CT-P6 + Herceptin + Paclitaxel
Phase 1/2Completed 2 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Feb 1, 2010 → Dec 1, 2023
NCT ID
NCT01084863About CT-P6 + Herceptin + Paclitaxel
CT-P6 + Herceptin + Paclitaxel is a phase 1/2 stage product being developed by Celltrion for Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01084863. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01084876 | Phase 3 | Completed |
| NCT01084863 | Phase 1/2 | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer